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BACKGROUND: Surfactant replacement therapy is a recognized treatment for respiratory distress syndrome (RDS) in the newborns. Over the past 
30 years, human and animal trials have been performed 
regarding administration of aerosolized surfactant to the 
injured lung, however the result has been unsatisfactory 
when compared with instilled surfactant delivery via 
endotracheal tube (ETT). This review aims to investigate 
the current issues, challenges and future recommendation of 
aerosolized surfactant therapy. 
CONTENT: Five randomized clinical trials in humans and 
13 animal trials met the inclusion criteria and were reviewed. 
Most animal trials agree that this method of treatment 
is feasible. However, human trials presented conflicting 
results, and generally showed it to be ineffective. When 
compared with surfactant delivery via ETT, aerosolized 
surfactant is less effective in improving respiratory function.
SUMMARY: The current data from human trials does not 
support the implementation of aerosolized surfactant therapy 
to treat newborns with RDS. Further research is necessary to 
improve nebulization, delivery, distribution and deposition 
in the lung, to investigate aerosolized surfactant delivery via 
ETT and to determine the appropriate dose.   
KEYWORDS: surfactant, aerosol, prematurity, respiratory 
distress syndrome
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LATAR BELAKANG: Terapi pemberian surfaktan adalah terapi yang sudah diakui untuk terapi sindrom distres pernapasan (SDP) pada bayi 
baru lahir. Selama lebih dari 30 tahun yang lalu, penelitian 
pemberian surfaktan secara aerosol telah dilakukan pada 
manusia dan hewan untuk mengobati kondisi paru, namun 
menunjukkan hasil yang kurang efektif bila dibandingkan 
dengan pemberian bolus surfaktan melalui endotracheal 
tube (ETT). Ulasan ini bertujuan untuk menyelidiki 
perkembangan terkini, tantangan, dan rekomendasi untuk 
terapi surfaktan secara aerosol di masa mendatang.
ISI: Lima randomized clinical trials pada manusia dan 13 
percobaan pada binatang memenuhi kriteria inklusi dan 
dikaji. Mayoritas percobaan pada binatang menunjukkan 
bahwa terapi ini memungkinkan, namun penelitian pada 
manusia memberikan hasil yang bervariasi, sebagian besar 
menunjukkan bahwa terapi ini tidak efektif. Pemberian 
surfaktan secara aeorosol kurang efektif jika dibandingkan 
dengan pemberian melalui (ETT), untuk memperbaiki 
fungsi paru.
RINGKASAN: Data terkini dari percobaan manusia tidak 
mendukung terapi pemberian surfaktan secara aerosol pada 
bayi dengan SDP. Penelitian lebih lanjut dibutuhkan untuk 
memperbaiki proses nebulisasi, pengiriman, distribusi serta 
deposisi partikel surfaktan di paru, menyelidiki pemberian 
surfaktan aerosol dengan memakai ETT, dan mencari dosis 
yang optimal. 
KATA KUNCI: surfaktan, aerosol, prematuritas, sindrom 
distres pernapasan
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Surfactant is a compound made from phospholipids in the 
alveoli of mammalian lungs.(1) Inside the lung, surface 
tension forces tend to cause alveoli to collapse. Laplace 
described the magnitude of the pressure (P) exerted at the 
wall of alveoli, as twice the surface tension (st) divided by 
the radius (r) of the curvature of the surface (P=2st/r).(2) 
Surfactant is produced by type 2 pneumocytes lining the 
alveoli.(3) Its function is to reduce surface tension, which 
provides alveolar stability, decreases opening pressure and 
increases lung compliance. It also enhances alveolar fluid 
clearance, decreases precapillary tone, and plays a protective 
role for the epithelial cell surface.(4,5) Deficiency in 
surfactant production or function in the newborn is termed 
respiratory distress syndrome (RDS)(6), and are more 
common in preterm newborns.
 The incidence of preterm birth (defined as delivery 
before 37 weeks of gestation)(7) in the United States of 
America is approximately 12–13% and 5–9% in other 
developed countries.(8) In Indonesia, the incidence of 
preterm birth varies from 9-14%, depending on the region.
(9,10) In general, there has been an increasing trend in 
preterm birth worldwide over the past decades. Prematurity 
is the single most common cause of RDS(11,12), the most 
common lung disease in preterm infants(6,13,14). The 
underdeveloped lung in the premature infant is characterized 
by insufficient alveolarisation, reduced functional surface 
area, widened distance between the alveolus and its adjacent 
capillary, deposition of fibrin into the air spaces, and 
pulmonary arteriolar muscularisation.(15) These structural 
abnormalities, combined with surfactant deficiency(16), 
cause alveolar instability and a tendency to collapse 
(atelectasis)(17), as well as capillary leak edema(16) and 
hyaline membrane formation.(6) These abnormalities lead to 
decreased pulmonary compliance, an increase in pulmonary 
morbidity, respiratory failure and ultimately death.
 Avery and Mead first discovered the relationship 
between surfactant deficiency and RDS in 1959. They 
reported that the surface active material recovered from the 
lungs of infants who died due to hyaline membrane disease 
(now known as RDS) was largely reduced in quantity.(18) 
RDS commonly affects babies born from 24 to 36 weeks 
of gestation.(19) After 24 weeks the terminal stage of lung 
development occurs: proliferation of the pulmonary vascular 
bed, formation of respiratory structures such as alveolar 
ducts and alveoli, and fusion of the gas exchange epithelium 
to the capillary epithelium.(19) Before this period, the 
fetal lungs are unable to provide any gas exchange. This 
explains the current threshold for viability of 24-25 weeks 
gestational age.(20)  In addition, type 2 pneumocytes do not 
appear before 32 to 34 weeks of gestation.(4) Therefore, 
these newborns will lack the ability to produce functional 
surfactant.
 Since the relationship between surfactant deficiency 
and RDS was established(18,21), research has focused on 
the development of surfactant, and method of delivery. 
In 1980, Fujiwara, et al.(22) achieved the first success in 
treating RDS using instilled surfactant. They treated 10 
preterm infants of gestational age (GA) 30.2 ± 0.6 weeks 
(mean ± standard deviation (SD)); birth weight (BW) 1,552 
± 104g (mean ± SD) diagnosed with RDS. The surfactant 
used was an organic solvent extract of bovine lung delivered 
endotracheally. After surfactant administration there was 
improvement in oxygenation, alveolar-arterial oxygen 
((A-a)O
2
) gradients and systemic hypotension and reversal 
of acidosis. After this success, much research addressed 
this new method of treatment(23-29) and now surfactant 
delivered endotracheally has become a standard treatment 
for the newborn with RDS(4,13,30).
Instillation vs. aerosolization method of surfactant 
delivery
The current method of surfactant delivery via endotracheal 
tube (ETT)(31-33) is associated with several adverse 
effects. Firstly, insertion of the ETT may cause mechanical 
injury to the dental lamina and larynx. Secondly, protrusion 
of the tip of the catheter risks injury to the trachea and 
bronchopulmonary infections. Thirdly, introduction of large 
volumes of liquid into an injured lung potentially causes 
harm(34) (e.g. bradycardia, hypoxia, increased pCO
2
, 
pulmonary hemorrhage, fluctuations in blood pressure)
(35,36). Fourthly, the fluid bolus effect may occur (the 
uneven distribution of surfactant as it makes its way through 
the airways).(37) These limitations generated research into 
the presumed gentler method of delivering surfactant via 
aerosol and continuous positive airway pressure (CPAP).
(38)
 The endotracheal delivery of surfactant in the newborn 
is performed by inserting a catheter into the ETT which 
lies above the infant’s carina.(39,40) Liquid surfactant is 
then injected through the catheter. The alternative method, 
aerosolized surfactant replacement therapy (SRT), utilizes 
undiluted surfactant(41) or surfactant diluted with sterile 
water(42,43), and aerosolizes it using a jet or ultrasonic 
nebulizer. The jet nebulizer (also known as small volume 
nebulizer (SVN))(44) creates an aerosol by delivering high 
pressure gas (air or oxygen) through the liquid surfactant 
and letting it flow through a narrow opening. The larger 
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Figure 1. CPAP system used for aerosolization of surfactant.(41) (Adapted with permission from John Wiley & Sons Ltd.)
Three databases: Web of Science (ISI), MEDLINE (ISI) and 
PubMed were searched for clinical trials which involved 
aerosolized SRT in human and animals. The keywords used 
were: surfactant replacement therapy, aerosolized surfactant 
replacement therapy, respiratory distress syndrome and 
premature/preterm infants. The search returned 65 results 
from Web of Science (ISI), 58 results from Medline (ISI), 
and 95 results from PubMed. Inclusion and exclusion 
criteria used were:
Human clinical trials
Inclusion criteria: 
1. Controlled or uncontrolled randomized clinical trial 
Methods
(RCT) which involved newborn participants with RDS. 
2. Aerosolized surfactant as the intervention.
3. Written in English.
Exclusion criteria:
1. Trials which recruited adult patients.
2. Infants with pulmonary disease other than RDS.
Animal trials
Inclusion criteria: 
1. Trials in any species of animal that is subjected to RDS.
2. Aerosolized surfactant was utilized for treatment. 
3. Written in English. 
Exclusion criteria:
1. Animals with a pulmonary disease model beside RDS.
 No year limit was given for both human and animal 
trials. Journal abstracts were screened for relevancy. If any 
article was found to be relevant, the full text for that article 
was retrieved. The reference list from relevant articles was 
searched manually.
 Five randomized clinical trials in humans and 13 
animal trials met the inclusion criteria and were included in 
this review.
particles break apart creating small, aerosolized particles.
(44) Ultrasonic nebulizers, on the other hand, use a high-
frequency sound wave to morph liquid into a fine mist 
(piezoelectric principle)(44), with the droplet size being 
determined by the frequency of the sound waves. The 
aerosolized surfactant product from either nebulizer is 
administered with CPAP via a bridging tube such as a T 
piece(41,45) (Figure 1) or modified connector(42,46), which 
is connected to a nasally inserted airway tube positioned just 
behind the soft palate(18-20,23). 
 CPAP flow varies from 1L/minute(41) to 8L/
minute(43). The time required for treatment ranges from 
20 minutes(41) to 6 hours(42), depending on the amount 
of surfactant delivered, the type of nebulizer, and the CPAP 
flow.
Results
Aerosolized SRT trials in newborns with RDS
To date, there have been five human trials of aerosolized 
surfactant in newborns with RDS. Jorch, et al.(41) 
conducted an uncontrolled multicenter pilot study from 
five neonatal departments in Germany, which involved 20 
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Table 1. Result of effects of nasopharyngeal surfactant aerosolization on respiratory parameters of infants with the respiratory 
distress syndrome on CPAP.(41) (Adapted with permission from John Wiley & Sons Ltd.)
Respiratory Rate 
(per minute) PaCO2 (mmHg) Silverman Score
(A-a)O2 gradient 
(mmHg)
     Before CPAP 56 ± 20 53 ± 16 5.9 ± 1.4 181 ± 101
     Before Nebulization 65 ± 18 52 ± 9 5.7 ± 1.3 163 ± 83
     After 150 mg/kg 56 ± 14 49 ± 9 4.6 ± 1.6 101 ± 73
     After 300 mg/kg 60 ± 15 51 ± 9 4.2 ± 1.8 121 ± 83
     30 minutes after 55 ± 18 48 ± 8* 3.5 ± 1.9* 117 ± 82*
     2 hours after 62 ± 16 47 ± 8 3.3 ± 1.9 128 ± 90
     4 hours after 63 ± 13 47 ± 9 3.5 ± 2.1 124 ± 99
     12 hours after 58 ± 13 46 ± 10 2.4 ± 1.7 107 ± 66
Data above are presented as means ± SD, *statistically significant improvement
low birth weight (LBW) premature infants (median BW 
1,680g, range 1,150-2,500g; median GA 31 weeks, range 
28-35 weeks) diagnosed with RDS. The study used 150 
mg/kg of undiluted natural bovine surfactant (Alveofact, 
Lyomark Pharma GmbH, Oberhaching, Germany). The 
authors reported a decrease in (A-a)O
2
 gradient, improved 
Silverman scores, an objective measurement of respiratory 
distress severity assessing the degree of chest retraction, 
xyphoid retraction, nasal dilatation, and grunt(47), and 
reduction in PaCO
2
 (Table 1). These improvements were 
sustained for up to 12 hours post treatment. However, six 
infants had to be intubated and mechanically ventilated and 
their responses were considered to be short lasting. In the 
good responders, the effect was permanent and the only 
adverse reaction found was increased pulmonary secretion 
during administration. No information was given about the 
baseline difference between these two groups, or any reason 
Figure 2. a/A PO2 in newborns with RDS treated with nebulized surfactant and in controls (Mean ± SD).(46) (Adapted with 
permission from John Wiley & Sons Ltd.)
for failure in the short lasting group.
 Berggren, et al.(46) performed a similar trial in 
32 newborns from six Swedish neonatal units. In this 
trial, 16 patients were randomized to a treatment group 
(CPAP combined with aerosolized surfactant (Curosurf, 
Cornerstone Therapeutics, Cary, NC) and 16 to a control 
group (CPAP only). Median BW and GA for both groups 
were similar. Despite a similar preparation method and 
nebulization process of the aerosolized surfactant, this 
trial did not show any beneficial effect of aerosolized SRT 
(Figure 2).
 Arroe, et al.(42) performed a trial using aerosolized 
surfactant (Exosurf, GlaxoSmithKline, London, UK) 
delivered by nasal CPAP (nCPAP). This uncontrolled trial 
involved 22 infants, (median BW 1,525g, range 520-2,721; 
median GA 31 weeks, range 23-36 weeks). The objective 
was to assess the improvement in oxygenation with different 
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dosages of surfactant. Infants with mild to moderate RDS 
(a/A ratios > 0.2) and no sign of infection, severe asphyxia, 
or congenital malformations were included. They were 
randomly assigned into four groups receiving either 2, 4, 5, 
or 8 vials of Exosurf in two divided doses six hours apart. 
There was no significant relationship between changes in a/A 
ratio, dose of Exosurf, or gestational age. During the trial, 
8 infants had to be intubated and mechanically ventilated. 
Two infants were intubated before the dose was completed 
due to pneumothoraces. Six others were intubated two 
hours after the treatment. Four of these were treated with 
additional instilled surfactant afterwards, however, only one 
infant showed improvement. The authors doubted whether 
surfactant administration was universally necessary in this 
group of preterm infants.
 In 2006, Finer, et al.(43) performed a trial which 
involved 17 neonates from four hospitals in the United 
States. Six infants were between 28-29 weeks GA, and 11 
infants were between 30-32 weeks GA. BW ranged from 
1,033 to 2,296 grams. The infants were given aerosolized 
Aerosurf via CPAP in the first 30 minutes of life. A low flow 
of 1L/minute was used.(41,46) Infants were randomized 
into two clusters: (1) three hours of treatment and a three 
hours break, repeated up to four times, and (2) three hours of 
treatment and a one hour break, repeated up to four times. No 
group served as a control. Eleven infants were successfully 
treated using a single dose of surfactant. All of the infants 
survived, however six required intubation and instilled 
surfactant administration. Of the 17 infants, four developed 
RDS at 24 hours, seven needed intermittent mechanical 
ventilation and two developed bronchopulmonary dysplasia 
at 28 days. Overall, the procedure was safe and did not show 
any side effects. Four years later, Finer, et al.(48) performed 
another trial involving 17 preterm infants at risk for RDS, 
using a novel vibrating membrane nebulizer Aeroneb Pro 
(Aerogen Ltd., Dangan, Ireland) to aerosolize 20 mg/mL 
of Aerosurf for three hours (volume of 15-54 mL), with 
retreatment separated by at least 1 or 3 hours. All infants 
survived, however 5 infants required additional endotracheal 
surfactant administration, 4 infants were diagnosed with 
RDS at 24 hours, and the mean FiO
2 
was 0.4 at baseline, and 
0.32 at 4 hours post treatment.
Animal trials of aerosolized surfactant
Numbers of experiments have been performed in 
different species of animals: rats(49-53), rabbits(54-56), 
lambs(57,58), and sheep(59-61) to test the feasibility of and 
response to aerosolized SRT in RDS. RDS in these animals 
was generated by methods including bronchoalveolar 
lavage (BAL) using saline solution(51,53,54,56,59-61), 
Escherichia coli endotoxin suspension injection(49,52), 
aspiration of acidified milk(50), and forced preterm 
delivery(55,57,58). In all animal trials, the animals 
were anaesthetized before one of the lung deterioration 
procedures was performed (except RDS caused by forced 
preterm delivery). Baseline values were recorded (e.g. 
PaO
2
), aerosolized surfactant was administered, and 
changes in lung function were measured over a designated 
period of time. The baseline PaO
2
 in each animal trial 
ranged from < 10 kPa(50), to 25 kPa(49), mimicking RDS. 
Aerosolized surfactant was delivered from either a jet(51, 
54) or an ultrasonic nebulizer(49,50,52,53,55,57,58,61). 
The types of surfactant used were modified natural surfactant 
(MNS) from bronchoalveolar lavage fluid of animals 
(49,50,52,53,55,57,58), Curosurf(51), Survanta (AbbVie 
Inc., North Chicago, IL)(54,57,59,60), Exosurf(54), or 
Alveofact(56) The ventilator settings in each trial were kept 
constant throughout.
 Lewis, et al.(57) performed a study to compare the 
efficacy of aerosolized MNS, aerosolized Survanta and 
endotracheal MNS in the treatment of preterm lambs. The 
aerosolized MNS and aerosolized Survanta groups had 
a significant increase in ventilation efficiency index and 
dynamic compliance. In addition, both groups achieved 
pressure-volume curves that were comparable to the instilled 
MNS group. Two years later, Lewis, et al. conducted a 
comparison of aerosolized versus instilled Survanta to saline-
lavaged adult sheep.(61) After an aerosolization period of 
3 hours with a dose of ~8mg/kg of surfactant, animals in 
the aerosolized surfactant group had significant increases 
in PaO
2
 at 150 and 180 minutes (p<0.01), and significant 
decreases in (A-a)O
2
 gradient at 120-180 minutes (p<0.05). 
Those improvements were slower compared to the instilled 
surfactant group who showed significant PaO
2 
increases at 
120 (p<0.05), 150 and 180 minutes (p<0.01), while the (A-a)
O
2
 gradient decreased at 90 (p<0.05) and 120–180 minutes 
(p<0.01). In addition, at the endpoint of the study (180 
minutes), the instilled surfactant group showed significantly 
higher PaO
2
 values (p<0.05), and lower (A-a)O
2
 gradients 
(p<0.05) compared to the aerosolized group.
 A trial using sheep born prematurely was performed 
by Henry, et al.(58) Initial assessment of lung function 
was performed at 15 minutes of age, and the sheep were 
grouped into two categories: low and moderate compliance. 
Subsequently, the sheep were randomized into three 
treatment groups: aerosolized surfactant only, instilled 
surfactant followed by aerosolized surfactant, and instilled 
surfactant followed by another instilled dose, and a control 
group. The instilled followed by aerosolized group showed 
that the deposition of aerosolized surfactant followed the 
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distribution pattern of the previously instilled surfactant. 
The aerosolized only group however, did not show uniform 
distribution, and very small clinical effect. They concluded 
that the distribution of aerosolized surfactant was related 
to the degree of lung maturation (the moderate compliance 
group showed better distribution), and the pattern of lung 
injury (less effective in a non-uniform pattern of lung 
injury).
 Lewis, et al.(59,60) carried out two trials in adult 
sheep with a non-uniform lung injury pattern, generated 
by isolating parts of the lung from the saline lung lavage 
procedure. These trials found that the aerosolized surfactant 
was preferentially deposited in the healthy region of the lung 
and very little in the injured part, which therefore reduced 
the overall effect. The group treated with instilled surfactant 
showed that liquid surfactant is able to penetrate to the 
unhealthy region of the lung, resulting in more deposition in 
the injured part of the lung and greater improvement in lung 
function parameters.
 Trials of aerosolized surfactant using rat models 
(49,51-53) used instilled surfactant as a comparison. 
Bahlamann, et al.(51) found that the effect of aerosolized 
surfactant differed between individual animals treated, 
from very little response to an improvement comparable 
with instilled surfactant treatment. However, the response 
was slower than that of instilled surfactant. This result is 
in concordance with the studies by Tashiro, et al.(49) and 
Dijk, et al.(56) who additionally reported that aerosolized 
surfactant administration did not cause significant changes 
in mean arterial blood pressure (MABP). In contrast, animals 
in the instilled group experienced a decrease in MABP 
of 25-30%(49,56) and a more severe decrease in cerebral 
blood flow(56). There was no difference in pulmonary blood 
flow between aerosolized or instilled surfactant groups.(56) 
In these 3 experiments, the therapeutic effect of instilled 
surfactant was still superior to aerosolized surfactant. 
The most recent trial by Tashiro, et al.(52) found that 
sustained amelioration in PaO
2
 was related to the duration 
of aerosolization (the group receiving aerosolization for 
up to 120 minutes had better PaO
2
 value at 180 minutes 
compared to the groups receiving aerosolization for 30 and 
60 minutes).
 Cui, et al.(50) combined aerosolized surfactant 
and aerosolized dextran in treating acute RDS caused by 
acidified milk in rats. In the surfactant only and surfactant 
plus dextran group, the PaO
2
 improved from <13 to >50 kPa 
after 30 minutes of treatment. However, the surfactant only 
group showed a gradual decline in PaO
2
 to <17 kPa at 180 
minutes, whereas it remained >38 kPa at 180 minutes in the 
surfactant plus dextran group.
 Fok, et al.(54) compared the effectiveness of 
aerosolized Exosurf and Survanta generated by either a jet 
or ultrasonic nebulizer in rabbits. They found that the group 
treated with Exosurf via jet nebulizer achieved the highest 
deposition of surfactant in the lung. The clinical effect, 
however, was limited and did not show significant benefit in 
treating RDS.
 Ellyett, et al.(55) administered dried surfactant to 
rabbits delivered prematurely at 27 days (normal gestation 
31 days). The surfactant preparation was generated by 
suspending surfactant in a sodium chloride solution, 
nebulizing and then drying it with radiant heat. This 
produces smaller particles with better ability to travel the 
upper airways. The dried aerosolized surfactant group 
had improved survival (67%), compared with the undried 
aerosolized surfactant (45%) or control (24%) groups.
Types of nebulizers and their challenges
Differences are noted between jet and ultrasonic nebulizers. 
Jet nebulizers have the advantage of using simple, tidal 
breathing, and are better for aerosolizing drug mixtures. 
However, the treatment time is longer.(62) Ultrasonic 
nebulizers, on the other hand, produce a higher rate of output 
that can deliver surfactant faster, but with larger particles 
generated.(63, 64) Drug concentration in the reservoir might 
increase with jet nebulizers (because of evaporation and 
recirculation), whereas it is more constant with ultrasonic 
nebulizers.(62,65) Jet nebulizers can be combined with low 
inspiratory flows and volume, therefore are more commonly 
used to nebulize drugs in newborns below two months of 
age (who have low flows and volume).(44,66) Finally, and 
most importantly, ultrasonic nebulizers generate energy 
that is dissipated as heat. Heat-sensitive proteins in the 
surfactant solution might therefore be denatured.(44) 
Despite these differences, there does not seem to be any 
correlation between the type of nebulizer and the outcome. 
More trials were performed with ultrasonic nebulizers than 
with jet nebulizers(6,11), however, all the trials in humans 
were performed using jet nebulizers.
Aerosolized surfactant particle diameter and activity
The mean diameter of aerosol particles in human trials 
(measured with low-angle scattering technique)(41,46) is 
generally < 4µm, which is considered ideal for deposition in 
central and terminal airways and alveoli(44,67).The aerosol 
product was highly effective in reducing surface tension 
when tested by a Wilhelmy-Langmuir balance (aerosolized 
surfactant is spread at the air-water interface and compressed 
by a teflon barrier. Reduction in attractive force as shown 
by the force transducer indicates low surface tension)(46) 
 97
Challenges in Aerosolized Surfactant Use in the Newborn (Samsudin DD)Indones  Biomed J.  2013; 5(2): 91-100DOI: 10.18585/inabj.v5i2.57
Ellyett, et al.(55) postulated that smaller particles will 
have maximum penetration but poor deposition and large 
particles poor penetration but good deposition in the lung. 
However, research has shown that even a mean diameter 
of 4µm produced a good response(41), whereas a much 
smaller particle (mean diameter 0.74µm) did not show any 
improvement in lung function(54). When compared with 
instilled surfactant, aerosolized surfactant takes a longer 
time to initiate treatment effect, and the lung improvement 
is not as effective as instilled surfactant.(50)
 Another point to consider is the change of environment 
from the nebulizer to the lung and its effect on the particle 
size. Inside the nebulizer device, aerosol is produced under 
relatively dry ambient conditions. Once in the airway, 
the temperature and humidity increase, and due to the 
hygroscopic (water absorbing molecule) nature of the 
aerosolized surfactant, the particle will grow in size.(44)
Types of surfactant used
The 17 trials in humans and animals use different surfactant 
preparations (e.g. Alveofact, Curosurf, Survanta and 
Exosurf).(68) The therapeutic effect of the same type of 
surfactant cannot be compared because there were not 
enough trials utilizing the same type of surfactant. However, 
most trials used natural surfactant derived from lung lavage 
fluid of animals (nine trials), including the study in humans 
that was shown to be successful by Jorch, et al.(18,26,33,34, 
36-40) Regarding the types of surfactant used, the lung 
improvements were inconsistent in human trials, and did not 
show any relation with overall mortality in human newborn 
trials.
Distribution and deposition of surfactant in the lung and 
the nebulizer equipment
Pulmonary deposition of aerosolized surfactant could 
not be assessed in human trials as biopsy is needed to 
accurately determine deposition. Surfactant deposition 
in animal lungs ranged from 0.4% in adult rats(51) to 
25% in preterm sheep(58). Surprisingly, even the lowest 
average pulmonary deposition of 0.46% is associated 
with significant improvement in lung function.(51) As for 
distribution, two animal trials in lambs(57) and sheep(61) 
found that aerosolized surfactant was distributed more 
evenly compared with instilled surfactant in a uniform 
pattern of lung injury.
 Jorch, et al.(41) estimated that only 10% of nebulized 
surfactant will enter the nCPAP tube. Given the total amount 
of surfactant used (345 to 750 mg), clinical improvement 
is thus due to approximately 35 to 75 mg of surfactant (per 
subject).(41) This is a major dose effective advantage of 
aerosolized surfactant, compared with the higher standard 
dose used in the instillation method for newborns.(47) 
However, a higher dose to be aerosolized is still required in 
the first place. Fuller, et al.(69) investigated the nebulization 
of radiolabelled saline delivered via ETT and found that 
50% of the total saline was deposited into a target chamber 
(which was designed to represent the lung).
 Surfactant labelled with radioactive technetium-99m 
pertechnetate(25,36,40) or [3H]choline(57) was used to 
assess the distribution pattern in the lung and the nebulizer 
or respiratory circuit. Ten percent(57) to 60%(49) of the 
total radioactivity (thus the surfactant) was found in the 
nebulization circuit and filter, T piece, expiratory tubing, 
carina, and trachea. Li, et al.(53) washed the expiratory 
tubing, nebulization filter and circuit to determine the 
phospholipid content. They found that 35-45% of the 
aerosolized surfactant was found in the filter of the nebulizer 
circuit, and 50-60% in the expiratory tubing as condensed 
liquid.(53) Apart from the surfactant that is deposited in 
the lung, the remaining surfactant was not found and was 
suggested to have escaped into the ambient air via the 
filter(49), or lost during expiration(41).
 Fok, et al.(54) suspected that surfactant which had 
condensed inside the ventilator tubing might be transferred 
into the lung during the ongoing ventilation process, causing 
further deposition of surfactant and clinical improvement. 
To investigate this theory, the ventilator tubing was 
positioned at a higher level than the animals. This produced 
significantly higher lung deposition of surfactant, and 
improvement in lung condition, than when ventilator 
tubing was positioned lower. Henry, et al.(58) applied a 
modified nebulizer which allowed aerosolized surfactant 
to be delivered only during inspiration, thus utilizing less 
surfactant materials. Therefore, improvement in nebulizer 
technology and equipment design is crucial to increase the 
efficiency of aerosolized surfactant delivery.
Internal factors of the newborn which may affect clinical 
response to aerosolized SRT
Some internal factors (respiratory structure and physiology) 
have been identified by these trials to provide some 
explanation for failure and key points for improvement. 
Those factors were: pattern of lung injury, lung maturation, 
plasma protein leakage into the airspaces of the lung, 
physiology of surfactant inside the lung and newborn 
breathing physiology.
 The nature of surfactant distribution using the 
aerosolized method follows the airway ventilation pattern. 
Normal, well-ventilated areas of the lung will achieve 
higher deposition of aerosolized surfactant. In non-uniform
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also provided insights into factors leading to successful 
treatment, and how to improve the aerosolized surfactant 
method.
Factors which influence effectiveness of aerosolized SRT
The improvement of lung function in human and animal 
trials varies broadly from no treatment effect(42,43,46) to 
a significant improvement comparable to the instillation 
method(41,51). This response appears to be independent 
of factors such as the diameter of surfactant particles 
generated, types of surfactant preparation used(70) and 
types of nebulizer used.
 Factors increasing the response to aerosolized 
surfactant include: the baseline condition of the baby 
(poorer initial condition leads to a worse prognosis)(41,51), 
the stage of lung maturation (more mature lung provides 
better ventilation and thus better distribution of surfactant)
(39,42,58), the underlying pattern of lung injury (more 
effective in a uniform pattern of lung injury)(58), the 
initiation time of therapy (earlier initiation of treatment 
offers a better prognosis)(41), the total amount of surfactant 
used (more surfactant administered leads to better clinical 
response)(52), and the duration of inhalation (longer 
inhalation period allows for greater improvement in gas 
exchange)(52).
 Modifications to the equipment such as delivering 
surfactant only during inspiration(58-60) or using low 
CPAP flow(43,60) showed increased efficiency in the usage 
of surfactant materials and gave higher dose-effectiveness. 
Addition of compounds such as dextran(50) or using dried 
surfactant(55) was demonstrated to provide additional 
benefit in animal trials however, these methods are not yet 
tested in human trials.
Advantages and disadvantages of aerosolized SRT
Advantages of aerosolized SRT that have been confirmed 
in human and animal trials are: firstly, it has better 
dose effectiveness if calculated by the actual amount 
of surfactant that is deposited in the lung.(50,51,60,61) 
Secondly, it is less invasive.(42) Thirdly, it produces less 
side effects such as no change in pulmonary blood flow(57) 
and no hypotension(49,56) compared with instilled 
surfactant. Fourthly, it is distributed more uniformly in a 
uniform pattern of lung injury.(42, 57, 61) Fifthly, it can 
be delivered to moderately sick babies without the need of 
intubation(42,51), and finally, it can be given continuously 
without disconnecting from the ventilator(42, 51).
 Disadvantages of aerosolized SRT as mentioned in 
these trials are: firstly, limited or negligible clinical effect.
(42,43,46,54,58) Secondly, it needs a long treatment period 
lung injury, the underventilated areas will receive less or 
no surfactant at all, and this determines the physiologic 
response to aerosolized SRT.(11, 26, 45-47) Henry, et al.(58) 
found a relationship between compliance of the lung and 
improvement in lung function. More compliant lungs are 
able to provide better ventilation and therefore distribution 
of aerosolized surfactant. Lung compliance is related to the 
degree of maturation of the lung, thus the gestational age.
 Bahlamann, et al.(51) recovered human albumin 
protein from post-mortem bronchoalveolar lavage fluid to 
determine the human albumin concentration (as an indicator 
of pulmonary vascular-to-alveolar protein leakage). They 
found that there was a significant negative correlation 
between the amount of human albumin (mg/kg) in the 
lavage fluid and final values for PaO
2
 (r=-0.67, p<005). 
This correlation was not shown in animals treated with 
instilled surfactant. It was concluded that the treatment 
effect depends on the quantity of surfactant delivered to 
the lung and the amount of plasma protein leakage to the 
same compartment. This did not occur in the instilled 
surfactant group because the large amount of surfactant 
counterbalanced the vascular-to-alveolar leak of surfactant 
inhibitors.(51) They also suggested that there was an 
underestimation in the aerosolized surfactant deposition 
analysis, because the surfactant materials quickly become 
lung-associated (cannot be recovered).(51) In addition, 
exogenous surfactant delivered as aerosol could stimulate 
endogenous surfactant production, which will sustain 
improvement of lung function over a period of time.(48-50)
It is important to understand that it is difficult to effectively 
compare these trials due to variations in factors affecting 
the outcomes (e.g. initiation time of therapy, difference in 
baseline conditions, type of surfactant used and delivery 
method, diversity of species in animal trials, etc). Therefore, 
this discussion intends to consider evidence from individual 
human and animal trials and identify the significant issues 
and challenges regarding the use and future development of 
aerosolized SRT.
Summary of trials in human newborns and animals
There are discrepancies in the outcomes of aerosolized 
surfactant trials in humans. Three trials(18,20,24) showed 
some benefit whereas the other two(42,46) did not show any 
improvement in lung function. On the other hand, animal 
trials have shown that aerosolized surfactant is effective 
in treating RDS with only two trials(54,58) reporting only 
minimal improvement in lung function. These trials have 
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Conclusion
Since the discovery of aerosolized surfactant for the 
treatment of RDS, there has been considerable progress 
in investigating the feasibility and development of this 
method. Despite some success in animal trials, aerosolized 
surfactant is not currently proven to be effective in treating 
newborns with RDS. Improvements in aerosolized 
medication technology could be expected to turn this 
circumstance around. For now, an essential approach would 
be to investigate how to improve surfactant distribution and 
deposition in the lung, to compare ETT and CPAP methods 
of delivery, determine the appropriate dose, and establish 
the appropriate population to treat. All these questions 
should be best answered by randomised controlled trials.
References
1. Zuo YY, Veldhuizen RA, Neumann AW, Petersen NO, Possmayer 
F. Current perspectives in pulmonary surfactant-inhibition, 
enhancement and evaluation. Biochim Biophys Acta. 2008; 1778: 
1947-77.
2. West JB. Respiratory physiology: the essentials. Philadelphia: 
Lippincott Williams & Wilkins; 2005.
3. Cole FS, Nogee LM, Hamvas A. Defects in surfactant synthesis: 
clinical implications. Pediatr Clin North Am. 2006; 53: 911-27.
4. Stevens TP, Sinkin RA. Surfactant replacement therapy. Chest. 2007; 
131: 1577-82.
5. Gupta S, Donn S. Novel Approaches to Surfactant Administration. Crit 
Care Res Pract. 2012; 2012: 278483.
6. Lissauer T, Fanaroff AA. Neonatology at a glance. Malden, 
Massachusetts: Blackwell Publishing; 2006.
7. Goldenberg RL, Culhane JF, Lams JD, Romero R. Epidemiology and 
causes of preterm birth. Lancet. 2008; 371: 75-84.
8. Slattery M, Morrison J. Preterm delivery. Lancet. 2002; 360: 1489-97.
9. Beck S, Wojdyla D, Say L, Betran A, Merialdi M, Requejo J, et al. 
The worldwide incidence of preterm birth: a systematic review of 
maternal mortality and morbidity. Bull World Health Organ. 2010; 
88: 31-8.
10. Bayi berat lahir rendah. In: Pudjiadi A, Hegar B, Handryastuti S, Idris 
N, Gandaputra E, Harmoniati E, editors. Pedoman pelayanan medis 
Jakarta: Ikatan Dokter Anak Indonesia; 2009. p. 23-9.
11. Haram K, Mortensen J, Wollen A. Preterm delivery: an overview. Acta 
Obstet Gynecol Scand. 2003; 82: 687-704.
12. Lal MK, Sinha S. Surfactant respiratory therapy using Surfaxin/
sinapultide. Ther Adv Respir Dis. 2008; 2(5): 339-44.
13. Lorraine B W, Michael A M. The acute respiratory distress syndrome. 
N Engl J Med. 2000; 342(18): 1334-49.
14. Notter R. Lung surfactants. Basic science and clinical applications. 
New York: Marcel Dekker, Inc; 2000.
15. Sinha S, Gupta S, Donn S. Immediate respiratory management of the 
preterm infant. Semin Fetal Neonatal Med. 2008; 13: 24-9.
16. Agrons GA, Courtney SE, Stocker JT, Markowitz RI. Lung disease 
in premature neonates: radiologic-pathologic correlation. 
Radiographics. 2005; 25(4): 1047-73.
17. Ballard PL, Merrill JD, Truog WE, Godinez RI, Godinez MH, McDevitt 
TM, et al. Surfactant function and composition in premature infants 
treated with inhaled nitric oxide. Pediatrics. 2007; 120: 346-53.
18. Avery ME, Mead J. Surface properties in relation to atelectasis and 
hyaline membrane disease. Am J Dis Child. 1959; 97: 517-23.
19. Merenstein GB, Gardner SL. Handbook of neonatal intensive care-
Fourth edition St. Louis, Missouri: Mosby-Year Book, Inc; 1998.
20. Vavasseur C, Foran A, Murphy JF. Consensus statements on the 
borderlands of neonatal viability: from uncertainty to grey areas. Ir 
Med J. 2007; 100(8): 561-4.
21. Brumley GW, Hodson WA, Avery ME. Lung phospholipids and surface 
tension correlations in infants with and without hyaline membrane 
disease and in adults. Pediatrics. 1967; 40: 13-9.
22. Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T. Artificial 
surfactant therapy in hyaline-membrane disease. Lancet. 1980; 1: 
55-9.
23. Kobayashi T, Kataoka H, Ueda T, Murakami S, Takada Y, Kokubo M. 
Effects of surfactant supplement and end-expiratory pressure in 
lung-lavaged rabbits. J Appl Physiol Respir Environ Exerc Physiol. 
1984; 57: 995-1001.
24. Berggren E, Lachmann B, Curstedt T, Grossmann G, Robertson B. 
Gas exchange and lung morphology after surfactant replacement 
in experimental adult respiratory distress syndrome induced by 
repeated lung lavage. Acta Anaesthesiol Scand. 1986; 30: 321-8.
25. Rey M, Segerer H, Kiessling C, Obladen M. Surfactant bolus 
instillation: effects of different doses on blood pressure and cerebral 
blood flow velocities. Biol Neonate. 1994; 66(1): 16-21.
26. Schipper JA, Mohammad GI, van Straaten HL, Koppe JG. The 
impact of surfactant replacement therapy on cerebral and systemic 
circulation and lung function. Eur J Pediatr. 1997; 156: 224-7.
27. Kendig JW, Ryan RM, Sinkin RA, Maniscalco WM, Notter RH, Guillet 
R, et al. Comparison of two strategies for surfactant prophylaxis in 
very premature infants: a multicenter randomized trial. Pediatrics. 
1998; 101(6): 1006-12.
28. Nuntnarumit P, Bada HS, Yang W, Korones SB. Cerebral blood flow 
velocity changes after bovine natural surfactant instillation. J 
Perinatol. 2000; 20(4): 240-3.
29. Halliday H. Recent clinical trials of surfactant treatment for neonates. 
Biol Neonate. 2006; 89: 323-9.
of three to six hours.(42,43,46,61) Thirdly, it utilizes a 
large volume of surfactant.(41,52,54) Fourthly, it is less 
effective in treating non-uniform patterns of lung injury.
(58-60) Fifthly, it has a slower initiation of clinical effect 
compared with instilled surfactant(49,52,53,61), and finally, 
it increases pulmonary secretions(41).
Challenges and future recommendations for aerosolized 
SRT
In reality, mild or moderate RDS may improve with CPAP 
alone. A useful approach would be to investigate the use of 
aerosolized surfactant in sicker (intubated and ventilated) 
infants, a population which would benefit the most from 
the surfactant therapy. This would require investigation of 
the delivery of aerosolized surfactant via ETT. Before this 
stage can occur, it is crucial to investigate the nebulization 
and delivery process to provide a more efficient use of 
aerosolized surfactant as well as better distribution and 
deposition in the lung.
100
The Indonesian Biomedical Journal, Vol.5, No.2, August 2013, p.91-100 ISSN: 2085-3297
30. Engle WA. Surfactant-replacement therapy for respiratory distress in 
the preterm and term neonate. Pediatrics. 2008; 121: 419-32.
31. Vidyasagar D, Velaphi S, Bhat V. Surfactant Replacement Therapy in 
Developing Countries. Neonatology. 2011; 99: 355 - 66.
32. Stevens TP, Blennow M, Myers EH, Soll R. Early surfactant 
administration with brief ventilation vs. selective surfactant and 
continued mechanical ventilation for preterm infants with or at risk 
for respiratory distress syndrome. Cochrane Database Syst Rev. 
2007; (4): CD003063.
33. Halliday H. Surfactants: past, present and future. J Perinatol. 2008; 28: 
S47-S56.
34. Lewis JF. In vivo studies of aerosolized exogenous surfactant. Aerosol 
Sci Technol. 1995; 22(4): 354-63.
35. Ware L, Matthay M. The acute respiratory distress syndrome. N Engl J 
Med. 2000; 342: 1334-49.
36. Lopez E, Gascoin G, Flamant C, Merhi M, Tourneux P, Baud O. 
Exogenous surfactant therapy in 2013: What is next? who, when 
and how should we treat newborns infants in the future? BMC 
Pediatr. 2013; 13: 165.
37. Espinosa FF, Kamm RD. Bolus dispersal through the lungs in surfactant 
replacement therapy. J Appl Physiol. 1999; 86(1): 391-410.
38. Pillow J, Micnocchieri S. Innovation in Surfactant Therapy II: 
Surfactant Administration by Aerosolization. Neonatology. 2012; 
101: 337-44.
39. Femitha P, Joy R, Adhisivam B, Prasad K, Gane BD, Bhat V. Surfactant 
Replacement Therapy (SRT) in Respiratory Distress Syndrome 
(RDS). Curr Pediatr Res. 2012; 16(2): 134-6.
40. Ramanathan R. Surfactant therapy in preterm infants with respiratory 
distress syndrome and in near-term or term newborns with acute 
RDS. J Perinatol. 2006; 26: 51-6.
41. Jorch G, Hartl H, Roth B, Kribs A, Gortner L, Schaible T, et al. 
Surfactant aerosol treatment of respiratory distress syndrome in 
spontaneously breathing premature infants. Pediatr Pulmonol. 
1997; 24: 222-4.
42. Arroe M, Pedersen-Bjergaard L, Albertsen P, Bode S, Greisen G, 
Jonsbo F, et al. Inhalation of aerosolized surfactant (Exosurf(R)) 
to neonates treated with nasal continuous positive airway pressure. 
Prenatal Neonatal Med. 1998; 3: 346-52.
43. Finer NN, Merritt TA, Bernstein G. A multicenter pilot study of Aerosurf 
delivered via nasal continuous positive airway pressure (nCPAP) to 
prevent respiratory distress syndrome in preterm neonates. Pediatr 
Res. 2006; 59: PAS2006: 4840.138.
44. Gardenhire D. Rau's respiratory care phamacology Rau JL, editor. St. 
Louis, Mo: Mosby/Elsevier; 2008.
45. Smedsaas-Löfvenberg A, Nilsson K, Moa G, Axelsson I. Nebulization 
of drugs in a nasal CPAP system. Acta Paediatr. 1999; 88: 89-92.
46. Berggren E, Liljedahl M, Winbladh B, Andreasson B, Curstedt T, 
Robertson B, et al. Pilot study of nebulized surfactant therapy for 
neonatal respiratory distress syndrome. Acta Paediatr. 2000; 89: 
460-4.
47. Mathai SCS, Raju CU, Kanitkar M. Management of respiratory distress 
in the newborn. Med J Armed Forces India. 2007; 63: 269-72.
48. Finer N, Merritt T, Bernstein G, Job L, Mazela J, Segal R. An open 
label, pilot study of Aerosurf (R) Combined with nCPAP to prevent 
RDS in preterm neonates. J Aerosol Med Pulm Drug Deliv. 2010; 5: 
303-9.
49. Tashiro K, Yamada K, Li W, Matsumoto Y, Kobayashi T. Aerosolized 
and instilled surfactant therapies for acute lung injury caused by 
intratracheal endotoxin in rats. Crit Care Med. 1996; 24: 488-94.
50. Cui X, Tashiro K, Matsumoto H, Tsubokawa Y, Kobayashi T. 
Aerosolized surfactant and dextran for experimental acute 
respiratory distress syndrome caused by acidified milk in rats. Acta 
Anaesthesiol Scand. 2003; 47: 853-60.
51. Bahlmann H, Sun B, Nilsson G, Curstedt T, Robertson B. Aerosolized 
surfactant in lung-lavaged adult rats: factors influencing the 
therapeutic response. Acta Anaesthesiol Scand. 2000; 44: 612-22.
52. Tashiro K, Yamada K, Konzaki T, Yamamoto K, Ohmura S, Kobayashi 
T, et al. Aerosolized surfactant therapy for endotoxin-induced 
experimental acute respiratory distress syndrome in rats. Br J 
Anaesth. 2001; 87(2): 266-71.
53. Li W, Chen W, Kobayashi T. Aerosolized surfactant reverses respiratory 
failure in lung-lavaged rats. Acta Anaesthesiol Scand. 1994; 38: 82-
8.
54. Fok TF, Al-Essa M, Dolovich M, Rasid F, Kirpalani H. Nebulisation of 
surfactants in an animal model of neonatal respiratory distress. Arch 
Dis Child Fetal Neonatal Ed. 1998; 78(F): F3-F9.
55. Ellyett KM, Broadbent RS, Fawcett ER, Campbell AJ. Surfactant 
aerosol treatment of respiratory distress for spontaneously breathing 
premature rabbit. Pediatr Res. 1996; 39: 953-7.
56. Dijk PH, Heikamp A, Bambang Oetomo S. Surfactant nebulisation 
prevents the adverse effects of surfactant therapy on blood pressure 
and cerebral blood flow in rabbits with severe respiratory failure. 
Intensive Care Med. 1997; 23: 1077-81.
57. Lewis JF, Ikegami M, Jobe A, Tabor B. Aerosolized surfactant treatment 
of preterm lambs. J Appl Physiol. 1991; 70: 869-76.
58. Henry MD, Rebello CM, Ikegami M, Jobe AH, Langenback EG, Davis 
JM. Ultrasonic nebulized in comparison with instilled surfactant 
treatment of preterm lambs. Am J Respir Crit Care Med. 1996; 154: 
366-75.
59. Lewis JF, Ikegami M, Jobe AH, Absolom D. Physiologic responses and 
distribution of aerosolized surfactant (Survanta) in a nonuniform 
pattern of lung injury. Am Rev Respir Dis. 1993; 147: 1364-70.
60. Lewis JF, McCaig L. Aerosolized versus instilled exogenous surfactant 
in a nonuniform pattern of lung injury. Am Rev Respir Dis. 1993; 
148: 1187-93.
61. Lewis JF, Tabor B, Ikegami M, Jobe AH, Joseph M, Absolom D. Lung 
function and surfactant distribution in saline-lavaged sheep given 
instilled vs. nebulized surfactant. J Appl Physiol. 1993; 74(3): 1256-
64.
62. Rau JL. Design principles of liquid nebulization devices currently in 
use. Respir Care. 2002; 47(1): 1257-75.
63. Asmus MJ, Milavetz G, Tice AL, Teresi ME. In vitro characteristics 
of tobramycin aerosol from ultrasonic and jet nebulizers. 
Pharmacotherapy. 2001; 21(5): 534-9.
64. Rau JL. Design principles of liquid nebulization devices currently in 
use. Respir Care. 2002; 47(11): 1257-75.
65. Steckel H, Eskandar F. Factors affecting aerosol performance during 
nebulization with jet and ultrasonic nebulizers. Eur J Pharm Sci. 
2003; 19(5): 443-55.
66. Adjei AL, Altiere RJ, Amin H, Asgharian B, Bernstein JA, Bhat M, 
et al. Inhalation aerosols: physical and biological basis of therapy 
second ed. Hickey A, editor. New York: Informa Healthcare; 2007.
67. Dolovich MA. Influence of inspiratory flow rate, particle size, and 
airway caliber on aerosolized drug delivery to the lung. Respir Care. 
2000; 45(6): 597-608.
68. Ma CC, Ma S. The Role of Surfactant in Respiratory Distress 
Syndrome. Open Respir Med J. 2012; 6: 44-53.
69. Fuller H, Dolovich M, Chambers C, Newhouse M. Aerosol delivery 
during mechanical ventilation: a predictive in-vitro lung model. J 
Aerosol Med. 1992; 5: 251.
70. Holm BA. Editorial: Surfactant replacement therapy, new level of 
understanding. Am Rev Respir Dis. 1993; 148: 834-6.
